PMCB icon

PharmaCyte Biotech
PMCB

Overview Fund Activity

32 hedge funds and large institutions have $2.35M invested in PharmaCyte Biotech in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
32
Holders Change
+1
Holders Change %
+3.23%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
9
Closed
3
Calls
$18K
Puts
$13K
Net Calls
+$5K
Net Calls Change
-$9K

Top Buyers

1
KPF
1
K2 Principal Fund
Ontario, Canada
$655K
2
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$47.6K
3
Squarepoint
3
Squarepoint
New York
$32.1K
4
Renaissance Technologies
4
Renaissance Technologies
New York
$82K
5
Vanguard Group
5
Vanguard Group
Pennsylvania
$370K

Top Sellers

1
SM
1
Sabby Management
Florida
$178K
2
BlackRock
2
BlackRock
New York
$62.1K
3
CL
3
CSS LLC
Illinois
$0
4
Citadel Advisors
4
Citadel Advisors
Florida
$61.8K
5
Geode Capital Management
5
Geode Capital Management
Massachusetts
$466K
Name Holding Trade Value Shares
Change 		Shares
Change %
Northwestern Mutual Wealth Management
26
Northwestern Mutual Wealth Management
Wisconsin
$30 +$30 +14 New
UBS Group
27
UBS Group
Switzerland
$29 +$9 +4 +44%
JPMorgan Chase & Co
28
JPMorgan Chase & Co
New York
$26 -$11 -5 -29%
Morgan Stanley
29
Morgan Stanley
New York
$18 +$11 +5 +167%
NA
30
NewEdge Advisors
Louisiana
$6 – – –
CL
31
CSS LLC
Illinois
– -$27.7K -13,186 Closed
CWA
32
Carolina Wealth Advisors
South Carolina
– -$4 -2 Closed
1
2